Pembrolizumab (+) Berahyaluronidase alfa Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: MK-3475A

Pipeline

Phase 3: 2

Top Sponsors

Merck Sharp & Dohme LLC2

Indications

Cancer2
Solid Tumors1
Hematologic Malignancies1
Lung Cancer1
Non Small Cell Lung Cancer1

Birmingham, Alabama1 trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Central Alabama Research ( Site 0108)

Phase 3

Tucson, Arizona1 trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Arizona Cancer Center at UMC North ( Site 0018)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.